Table 3 Patient characteristics and treatment
From: Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Patient No. | Age range | Diagnosis | Prior lines of treatment | Conditioning regimen before T cell infusion | CAR-T dosage |
|---|---|---|---|---|---|
F0104 | 50–65 | FL/II | > 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0106 | 50–65 | DLBCL | > 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0107 | < 50 | FL/II | 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0109 | 50–65 | DLBCL | > 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0110 | 50–65 | MZL | > 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0111 | < 50 | DLBCL | > 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0118 | < 50 | DLBCL | > 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0119 | 50–65 | DLBCL | > 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0121 | < 65 | DLBCL | 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0122 | 50–65 | DLBCL | 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0123 | 50–65 | DLBCL | 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0125 | 50–65 | DLBCL | 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |
F0126 | < 50 | DLBCL | 2 | Flu25mg/m2 + CTX250mg/m2 | 1 × 106/kg |